At a time when Buy Now Pay Later companies have disrupted the Australian credit economy, Cash Converters (ASX: CCV) is making a strong comeback in the personal finance sector having transitioned away from their image as opportunistic pawnbrokers. The renaissance of Cash Converters which has increased marketing spend, evidenced through television advertising that features prominent
Read More
The keto diet is proving to be more than just another “It” diet touted by Goop with interesting research showing that it may have a place in cancer treatment. Eating a keto diet puts the body in a state of ketogenesis where instead of running off glucose based energy, the body is fueled by fats
Read More
A new treatment for the deadly bone marrow cancer myelofibrosis is one step closer to a FDA application with clinical stage drug development company Pharmaxis (ASX: PXS) having successfully completed dosing of the first stage of its current trial. With the first dosing of PXS-5505 confirmed as safe by the study’s safety monitoring committee, Pharmaxis
Read More
With initial plans to list in the Australian market last year furloughed by the pandemic, Israeli tech company Gefen Technologies is finally joining the dozen Israeli companies on the ASX, having closed their $25 million IPO at the end of last month. Israel is renowned for their ‘start up culture’, especially in tech, having produced
Read More
In a deal that has taken many years to execute, online price comparison company iSelect (ASX: ISU) has finally secured an affiliate marketing deal to promote Bupa, Canstar’s ‘Outstanding Value Health Insurance’ National Award winner for 13 years running. Given the public accolades won over the past decade as a household name across Australia, it’s
Read More
Traditional chemotherapy and radiotherapy have long been the standard of care for cancer treatment, but it’s no secret that there are numerous, debilitating side effects to a patient’s physical and mental health. Both are oftentimes ineffective with several cancers exhibiting poor responsiveness to traditional treatment. Clinical-stage drug development company Noxopharm (ASX: NOX) is addressing this
Read More